ORM 12741

Drug Profile

ORM 12741

Alternative Names: ORM-12741

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orion
  • Developer Janssen Pharmaceuticals; Orion; University of Cape Town; University of Oxford
  • Class Antipsychotics
  • Mechanism of Action Alpha 2c adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • No development reported Schizophrenia
  • Discontinued Raynaud's disease

Most Recent Events

  • 23 Mar 2018 Phase-I clinical trials in Alzheimer's disease (In volunteers) in South Africa (PO) (NCT03440021)
  • 26 Feb 2018 University of Cape Town, Orion Corporation and University of Oxford plans the SNAP_MRI phase I trial in healthy volunteers in South Africa (NCT03440021)
  • 07 Feb 2018 Orion completes a phase II trial in Alzheimer's disease in Finland, Germany, Czech Republic, Poland, Bulgaria, Croatia, and Romania (PO, capsule; immediate-release and modified-release) (NCT02471196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top